Clinical Trial Update: Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy, safety and immunogenicity of recombinant human C1 esterase inhibitor for the treatment of acute hereditary angioedema att…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Rhucin (conestat alfa)

Snippet

Sponsor: Pharming Technologies B.V. | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2015-08-07